Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells

Breast cancer is a major disease for women worldwide, where mortality is associated with tumour cell dissemination to distant organs. While the number of efficient anticancer therapies increased in the past 20 years, treatments targeting the invasive properties of metastatic tumour cells are still a...

Full description

Bibliographic Details
Main Authors: Eric Macia, Monserrat Vazquez-Rojas, Alessia Robiolo, Racha Fayad, Sophie Abélanet, Isabelle Mus-Veteau, Fabien Fontaine-Vive, Mohamed Mehiri, Frédéric Luton, Michel Franco
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/26/4/969
id doaj-e4d3d005e5dc453380a0885aa347ff2e
record_format Article
spelling doaj-e4d3d005e5dc453380a0885aa347ff2e2021-02-13T00:00:59ZengMDPI AGMolecules1420-30492021-02-012696996910.3390/molecules26040969Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer CellsEric Macia0Monserrat Vazquez-Rojas1Alessia Robiolo2Racha Fayad3Sophie Abélanet4Isabelle Mus-Veteau5Fabien Fontaine-Vive6Mohamed Mehiri7Frédéric Luton8Michel Franco9Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Chimie de Nice (ICN), UMR 7272 CNRS-Université Côte d’Azur, 28, avenue de Valrose, CEDEX 2, 06108 Nice, FranceInstitut de Chimie de Nice (ICN), UMR 7272 CNRS-Université Côte d’Azur, 28, avenue de Valrose, CEDEX 2, 06108 Nice, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceInstitut de Pharmacologie Moléculaire et Cellulaire (IPMC), UMR 7275 CNRS-Université Côte d’Azur, 660, route des lucioles, 06560 Valbonne, FranceBreast cancer is a major disease for women worldwide, where mortality is associated with tumour cell dissemination to distant organs. While the number of efficient anticancer therapies increased in the past 20 years, treatments targeting the invasive properties of metastatic tumour cells are still awaited. Various studies analysing invasive breast cancer cell lines have demonstrated that Arf6 is an important player of the migratory and invasive processes. These observations make Arf6 and its regulators potential therapeutic targets. As of today, no drug effective against Arf6 has been identified, with one explanation being that the activation of Arf6 is dependent on the presence of lipid membranes that are rarely included in drug screening. To overcome this issue we have set up a fluorescence-based high throughput screening that follows overtime the activation of Arf6 at the surface of lipid membranes. Using this unique screening assay, we isolated several compounds that affect Arf6 activation, among which the antibiotic chlortetracycline (CTC) appeared to be the most promising. In this report, we describe CTC in vitro biochemical characterization and show that it blocks both the Arf6-stimulated collective migration and cell invasion in a 3D collagen I gel of the invasive breast cancer cell line MDA-MB-231. Thus, CTC appears as a promising hit to target deadly metastatic dissemination and a powerful tool to unravel the molecular mechanisms of Arf6-mediated invasive processes.https://www.mdpi.com/1420-3049/26/4/969small G proteininhibitorcell invasionArf6breast cancerchlortetracycline
collection DOAJ
language English
format Article
sources DOAJ
author Eric Macia
Monserrat Vazquez-Rojas
Alessia Robiolo
Racha Fayad
Sophie Abélanet
Isabelle Mus-Veteau
Fabien Fontaine-Vive
Mohamed Mehiri
Frédéric Luton
Michel Franco
spellingShingle Eric Macia
Monserrat Vazquez-Rojas
Alessia Robiolo
Racha Fayad
Sophie Abélanet
Isabelle Mus-Veteau
Fabien Fontaine-Vive
Mohamed Mehiri
Frédéric Luton
Michel Franco
Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells
Molecules
small G protein
inhibitor
cell invasion
Arf6
breast cancer
chlortetracycline
author_facet Eric Macia
Monserrat Vazquez-Rojas
Alessia Robiolo
Racha Fayad
Sophie Abélanet
Isabelle Mus-Veteau
Fabien Fontaine-Vive
Mohamed Mehiri
Frédéric Luton
Michel Franco
author_sort Eric Macia
title Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells
title_short Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells
title_full Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells
title_fullStr Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells
title_full_unstemmed Chlortetracycline, a Novel Arf Inhibitor that Decreases the Arf6-Dependent Invasive Properties of Breast Cancer Cells
title_sort chlortetracycline, a novel arf inhibitor that decreases the arf6-dependent invasive properties of breast cancer cells
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2021-02-01
description Breast cancer is a major disease for women worldwide, where mortality is associated with tumour cell dissemination to distant organs. While the number of efficient anticancer therapies increased in the past 20 years, treatments targeting the invasive properties of metastatic tumour cells are still awaited. Various studies analysing invasive breast cancer cell lines have demonstrated that Arf6 is an important player of the migratory and invasive processes. These observations make Arf6 and its regulators potential therapeutic targets. As of today, no drug effective against Arf6 has been identified, with one explanation being that the activation of Arf6 is dependent on the presence of lipid membranes that are rarely included in drug screening. To overcome this issue we have set up a fluorescence-based high throughput screening that follows overtime the activation of Arf6 at the surface of lipid membranes. Using this unique screening assay, we isolated several compounds that affect Arf6 activation, among which the antibiotic chlortetracycline (CTC) appeared to be the most promising. In this report, we describe CTC in vitro biochemical characterization and show that it blocks both the Arf6-stimulated collective migration and cell invasion in a 3D collagen I gel of the invasive breast cancer cell line MDA-MB-231. Thus, CTC appears as a promising hit to target deadly metastatic dissemination and a powerful tool to unravel the molecular mechanisms of Arf6-mediated invasive processes.
topic small G protein
inhibitor
cell invasion
Arf6
breast cancer
chlortetracycline
url https://www.mdpi.com/1420-3049/26/4/969
work_keys_str_mv AT ericmacia chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells
AT monserratvazquezrojas chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells
AT alessiarobiolo chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells
AT rachafayad chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells
AT sophieabelanet chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells
AT isabellemusveteau chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells
AT fabienfontainevive chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells
AT mohamedmehiri chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells
AT fredericluton chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells
AT michelfranco chlortetracyclineanovelarfinhibitorthatdecreasesthearf6dependentinvasivepropertiesofbreastcancercells
_version_ 1724272652546211840